Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9958649 | 0.96 | NOTUM (0.50) | NOTUMMAPTLMNANPC1RAB9A | |
| SCHEMBL9958407 | 0.85 | NOTUM (0.48) | NOTUMMAPTLMNANPC1RAB9A | |
| SCHEMBL9958209 | 0.84 | NOTUM (0.41) | NOTUMMAPTLMNANPC1RAB9A | |
| SCHEMBL38202 | 0.80 | ALDH1A1 (0.42) | NOTUMMAPTLMNANPC1RAB9A | |
| SCHEMBL41140 | 0.80 | ALDH1A1 (0.42) | NOTUMMAPTLMNANPC1RAB9A | |
| SCHEMBL183516 | 0.80 | ALDH1A1 (0.35) | RAB9AALDH1A1KMT2A | |
| SCHEMBL28544762 | 0.78 | ALDH1A1 (0.40) | NOTUMMAPTLMNANPC1RAB9A | |
| SCHEMBL38500 | 0.77 | CYP2A6 (0.54) | MAPTLMNANPC1RAB9ACYP1A2 | |
| SCHEMBL10013004 | 0.77 | HDAC4 (0.35) | — | |
| SCHEMBL9958537 | 0.77 | CYP2A6 (0.54) | MAPTLMNANPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115746316-B | Zinc fluorescent metal organic framework material with high recognition performance on aluminum ions and preparation method thereof | 盐城师范学院 | 2023-07-11 | — | — | CN | claimed |
| CN-114437087-B | N-containing organic compound and application thereof in organic light-emitting device and panel | 武汉天马微电子有限公司 | 2023-06-30 | — | — | CN | claimed |
| CN-116113255-A | Organic electroluminescent device, preparation method thereof and panel | 湖北长江新型显示产业创新中心有限公司 | 2023-05-12 | — | — | CN | claimed |
| CN-115746316-A | Zinc fluorescent metal organic framework material with high aluminum ion recognition performance and preparation method thereof | 盐城师范学院 | 2023-03-07 | — | — | CN | claimed |
| CN-114437087-A | N-containing organic compound and application thereof in organic light-emitting device and panel | 武汉天马微电子有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-113880818-A | Organic compound and blue light organic electroluminescent device | 机光科技股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| CN-113735789-A | Organic compound and red organic electroluminescent device | 机光科技股份有限公司 | 2021-12-03 | — | — | CN | claimed |
| CN-108117495-B | Spirofluorene ring compound, use thereof, and organic electroluminescent device using the same | 北京鼎材科技有限公司 | 2021-11-19 | — | — | CN | claimed |
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | REATA PHARMACEUTICALS, INC. (US) | 2021-09-23 | — | — | US | claimed |
| EP-3807265-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | Reata Pharmaceuticals, Inc. (US) | 2021-04-21 | — | — | EP | claimed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-6030969-A | ADENOSINE KINASE INHIBITORS; ANTIISCHEMIA,-INFLAMMATORY, -DIABETIC AGENTS; NEUROLOGICAL AND GASTROINTESTINAL DISORDERS; NOCIPERCEPTION, IMMUNOSUPPRESSION; SEPSIS | ABBOTT LABORATORIES (US) | 2000-02-29 | — | — | US | claimed |
| EP-0979230-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-16 | — | — | EP | claimed |
| EP-0975633-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL 2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-02 | — | — | EP | claimed |
| CN-1230175-A | Cytostatic hydroximic acid derivatives | BRITISH BIOTECH PHARM (GB) | 1999-09-29 | — | — | CN | claimed |
| WO-1998046604-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | claimed |
| WO-1998046603-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | claimed |
| CN-1173170-A | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1998-02-11 | — | — | CN | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292281-A1 | PYRAZOLE AND IMIDAZOLE COMPOUNDS FOR INHIBITION OF IL-17 AND RORGAMMA | RORC, RORB, RORA | NOTUM 3176/4885MAPT 2396/4885LMNA 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.